Table 2.

Treatment recommendations and hospitalization policies for imported, uncomplicated falciparum malaria in selected European countries

	First-line	Hospitalization policy
	treatment	Recommendations (R) or standard practice (SP)
Belgium	Atovaquone-proguanilArtemether-lumefantrine	SP : hospitalization (ambulatory treatment possible under certain conditions)
	Quinine + cycline
France	Atovaquone-proguanil Artemether-lumefantrine	R : Ambulatory treatment possible on the basis of specific clinical and biological parameters
Germany	Atovaquone-proguanil Artemether-lumefantrine	R : hospitalization recommended until treatment completed and patient parasite-free
	Mefloquine
Italy	Atovaquone-proguanil	SP : hospitalization (ambulatory treatment possible under certain conditions)
	Mefloquine
Spain	Quinine + cycline or clindamycin Atovaquone-proguanil	SP: hospitalization (ambulatory treatment possible under certain conditions)
Switzerland	Artemether-lumefantrine Atovaquone-proguanil	SP: hospitalization (ambulatory treatment possible under certain conditions)
United Kingdom	Atovaquone-proguanil	R : Systematically, at least 24 h
	Artemether-lumefantrine
	Quinine + cyclines
The Netherlands	Atovaquone-proguanil Artemether-lumefantrine	SP: hospitalization (ambulatory treatment possible under certain conditions)
	Quinine + cyclines
	Chloroquine*

*selected areas with known chloroquine-sensitive P. falciparum, e.g. Central America.